Page 3 - Van Rompay News Today

Hyloris Announces Commercial Partnership for Maxigesic® IV in 9 European Countries - read this article along with other careers information, tips and advice on BioSpace

01.09.2022 - - On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic IV - Focused entry into US market with Maxigesic IV for non-opioid pain treatment; continuing ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS... | April 1, 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Patient-friendly alternative to continuous IV administration – proven safety and efficacyTargeting orphan, late-stage heart failure indication with high...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Regulatory approvals in South Korea, the fourth largest pharma market in Asia, and PanamaMaxigesic® IV provides a non-opioid, dual mode-of-action pain management alternative to traditional analgesics ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT  On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinica...